- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07551362
이중 타겟 CLDN18.2/HER2 CAR-NK 세포 치료제를 이용한 진행성 위암/위식도 접합부암 치료 (DUET-GEJ)
A Phase 1/2, Open-label, Multicenter Study of Allogeneic Dual-target CLDN18.2/HER2 (ERBB2) CAR-NK Cells
This study proposes a phase 1/2 evaluation of an allogeneic, cord-blood-derived dual-target CAR-NK product directed against CLDN18.2 and HER2 (ERBB2) in adults with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma after prior standard systemic therapy. CLDN18.2 is selected as the anchor antigen because it has the more disease-specific gastric/GEJ cell-therapy development footprint, while HER2 is retained as the complementary second antigen to address co-expressing or heterogeneous disease. Phase 1 uses a 3+3 dose-escalation design after fludarabine/cyclophosphamide lymphodepletion followed by three intravenous CAR-NK infusions on Days 0, 3, and 7. Phase 2 expansion evaluates the recommended phase 2 dose and preliminary antitumor activity
연구 개요
상태
상세 설명
This study is based on current CLDN18.2- and HER2-directed cell-therapy CAR-T cell therapies. The key strategic choice is that HER2 and ERBB2 are treated as the same target; therefore, the meaningful dual-target construct in gastric/GEJ cancer is CLDN18.2 plus HER2. The study is designed as a biomarker-driven, non-randomized phase 1/2 program. In phase 1, patients will receive fludarabine/cyclophosphamide lymphodepletion on Days -5 to -3, followed by three infusions of EB-DT-CAR-NK on Days 0, 3, and 7. A 3+3 dose-escalation structure with three planned dose levels will be used to determine dose-limiting toxicities, maximum tolerated dose, and/or recommended phase 2 dose.
In phase 2, patients will receive the recommended dose on the same schedule in an expansion cohort focused on CLDN18.2-positive gastric/GEJ adenocarcinoma, with prespecified subgroup analyses by HER2 status. The study will assess safety, objective response rate, disease control, durability, survival outcomes, and CAR-NK expansion/persistence. Correlative studies will explore the relationship between baseline CLDN18.2/HER2 expression and clinical outcome.
연구 유형
등록 (추정된)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: shan S Lu, Phd
- 전화번호: +86 13076790030
- 이메일: Seni-Lu@beijing-biotech.com
연구 장소
-
-
Guangdong
-
Shenzhen, Guangdong, 중국, 518036
- 모병
- Peking University Shenzhen Hospital
-
연락하다:
- Zhen J Peng, Phd
- 전화번호: +86 13076790039
- 이메일: Zhen-Peng@beijing-biotech.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Signed informed consent before any study-specific procedure.
- Age 18 to 75 years.
- Histologically confirmed unresectable locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.
- Central confirmation of CLDN18.2-positive disease by immunohistochemistry, defined for this draft as membranous CLDN18.2 expression in at least 10% of tumor cells. HER2 testing is required for all subjects; HER2-positive disease is defined as IHC 3+ or IHC 2+/ISH+ using gastric/GEJ testing criteria.
- Disease progression after at least 2 prior systemic regimens for advanced disease, including a fluoropyrimidine and platinum agent unless contraindicated or not tolerated. If HER2-positive, prior HER2-directed therapy is expected unless unavailable, contraindicated, or not tolerated.
- At least 1 measurable lesion according to RECIST v1.1.
- ECOG performance status 0 or 1.
- Life expectancy of at least 12 weeks.
- Adequate hematologic, renal, hepatic, pulmonary, and cardiac function.
- Recovery of prior treatment-related toxicities to Grade 1 or baseline, except alopecia or stable endocrine replacement therapy.
- Willingness to provide archival tumor tissue or fresh biopsy material if archival tissue is inadequate for central biomarker confirmation.
- Negative pregnancy test for women of childbearing potential and agreement to use effective contraception during the protocol-defined period
Exclusion Criteria:
- Prior CLDN18.2-targeted or HER2-targeted genetically modified cell therapy (CAR-T, CAR-NK, TCR-T, or similar).
- Active or untreated central nervous system metastases or leptomeningeal disease.
- Active uncontrolled infection, including uncontrolled HBV, HCV, or HIV viremia.
- Active autoimmune disease requiring systemic immunosuppression.
- Clinically significant uncontrolled cardiovascular disease, including recent myocardial infarction, unstable angina, uncontrolled arrhythmia, or severe heart failure.
- Active gastrointestinal perforation, uncontrolled upper GI bleeding, clinically significant bowel obstruction, or unstable gastric ulcer.
- History of solid-organ transplantation or prior allogeneic hematopoietic stem-cell transplantation with active graft-versus-host disease.
- Requirement for systemic corticosteroids above physiologic replacement (for example, >10 mg/day prednisone equivalent) within 7 days before lymphodepletion.
- Pregnancy or breastfeeding.
- Another active malignancy requiring systemic therapy, except for adequately treated non-melanoma skin cancer, carcinoma in situ, or other protocol-allowed low-risk malignancies.
- Any medical, psychiatric, or social condition that, in the investigator's judgment, would make study participation unsafe or would interfere with interpretation of study results.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Dose Escalation Cohort
Participants receive fludarabine and cyclophosphamide lymphodepletion on Days -5 to -3, followed by EB-DT-CAR-NK infusions on Days 0, 3, and 7. Three planned dose levels are explored using a 3+3 design. |
Allogeneic, cord-blood-derived CAR-NK cells engineered to target CLDN18.2 and HER2 (ERBB2). Planned phase 1 dose levels: 2 x 10^6, 4 x 10^6, and 8 x 10^6 cells/kg/infusion. Administered intravenously on Days 0, 3, and 7. Lymphodepleting chemotherapy administered intravenously at 30 mg/m^2/day on Days -5 to -3.
다른 이름들:
Lymphodepleting chemotherapy administered intravenously at 500 mg/m^2/day on Days -5 to -3.
다른 이름들:
|
|
실험적: Dose Expansion Cohort
Participants receive the recommended phase 2 dose (RP2D) on the same lymphodepletion and infusion schedule. Expansion is centered on CLDN18.2-positive gastric/GEJ adenocarcinoma, with HER2 status captured for exploratory subgroup analysis. |
Allogeneic, cord-blood-derived CAR-NK cells engineered to target CLDN18.2 and HER2 (ERBB2). Planned phase 1 dose levels: 2 x 10^6, 4 x 10^6, and 8 x 10^6 cells/kg/infusion. Administered intravenously on Days 0, 3, and 7. Lymphodepleting chemotherapy administered intravenously at 30 mg/m^2/day on Days -5 to -3.
다른 이름들:
Lymphodepleting chemotherapy administered intravenously at 500 mg/m^2/day on Days -5 to -3.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of dose-limiting toxicities (DLTs)
기간: 28 days
|
DLTs graded by CTCAE v5.0, with CRS and ICANS graded using ASTCT criteria. |
28 days
|
|
Determination of MTD
기간: 6 months
|
Dose-escalation decision based on DLT frequency and overall tolerability across planned cohorts. |
6 months
|
|
Objective response rate (ORR)
기간: 12 months
|
Confirmed complete response plus partial response according to RECIST v1.1 in evaluable subjects in the expansion cohort. |
12 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-free survival (PFS)
기간: 12 months
|
Time from first infusion to disease progression or death from any cause. |
12 months
|
|
Overall survival (OS)
기간: 24 months
|
Time from first infusion to death from any cause. |
24 months
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- ESSEN-DUET-GEJ-117
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .